Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

pyoderma gangrenosum - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

pyoderma gangrenosum

MONDO:0018824

Find Clinical TrialsTrials

Overview

Pyoderma gangrenosum (PG) is a primarily sterile inflammatory neutrophilic dermatosis characterized by recurrent cutaneous ulcerations with a mucopurulent or hemorrhagic exudate.

TreatmentsNo approved treatments · 4 in pipeline

Clinical Trials8 registered · 2 recruiting

Diagnosis

Biomarker and diagnostic research for pyoderma gangrenosum has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for pyoderma gangrenosum. An additional 4 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for pyoderma gangrenosum, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for pyoderma gangrenosum. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

8 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, and medical devices. Pipeline includes 1 PHASE4, 1 PHASE3, 5 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07337564](https://clinicaltrials.gov/study/NCT07337564)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 10:41 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:48104

GARD

Genetic and Rare Diseases Info Center

GARD:7510

Questions for Your Care Team

→Are any of the 8 active clinical trials a good fit for my situation?
→With 4 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	60	33%
Research summaries	58	32%
Other research	23	13%
Disease patterns and progression	18	10%
Clinical study results	8	4%
Laboratory research	7	4%
Testing and diagnosis research	5	3%
New treatment approaches	2	1%

Kisho

pyoderma gangrenosum

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Atypical Visceral Involvement of Pyoderma Gangrenosum.

Guselkumab as a Treatment Adjunct for Pyoderma Gangrenosum While Maintaining Clinical Remission of Ulcerative Colitis.

Pyoderma Gangrenosum Phenotype Classification.

pyoderma gangrenosum

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Atypical Visceral Involvement of Pyoderma Gangrenosum.

Guselkumab as a Treatment Adjunct for Pyoderma Gangrenosum While Maintaining Clinical Remission of Ulcerative Colitis.

Pyoderma Gangrenosum Phenotype Classification.